Amy Elazzouzi Sells 1,404 Shares of Aura Biosciences, Inc. (NASDAQ:AURA) Stock

Aura Biosciences, Inc. (NASDAQ:AURA) SVP Amy Elazzouzi sold 1,404 shares of the stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $7.75, for a total value of $10,881.00. Following the sale, the senior vice president now directly owns 82,278 shares in the company, valued at approximately $637,654.50. The trade was a 1.68 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Amy Elazzouzi also recently made the following trade(s):

• On Tuesday, January 21st, Amy Elazzouzi sold 1,001 shares of Aura Biosciences stock. The shares were sold at an average price of $7.67, for a total value of $7,677.67.

Aura Biosciences Stock Performance

Shares of NASDAQ:AURA opened at $7.65 on Thursday. The stock’s 50-day moving average price is $8.02 and its two-hundred day moving average price is $8.74. Aura Biosciences, Inc. has a 12-month low of $6.63 and a 12-month high of $12.38. The firm has a market cap of $382.12 million, a price-to-earnings ratio of -4.42 and a beta of 0.29.

Analyst Upgrades and Downgrades

AURA has been the topic of a number of analyst reports. Lifesci Capital raised Aura Biosciences to a “strong-buy” rating in a research note on Friday, January 31st. HC Wainwright reissued a “buy” rating and issued a $22.00 price target on shares of Aura Biosciences in a research note on Thursday, November 14th. Five equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Aura Biosciences has an average rating of “Buy” and an average price target of $23.00.

Hedge Funds Weigh In On Aura Biosciences

Hedge funds and other institutional investors have recently modified their holdings of the company. BNP Paribas Financial Markets acquired a new position in shares of Aura Biosciences in the 4th quarter valued at about $50,000. China Universal Asset Management Co. Ltd. acquired a new position in shares of Aura Biosciences in the 4th quarter valued at about $87,000. ProShare Advisors LLC acquired a new position in shares of Aura Biosciences in the 4th quarter valued at about $127,000. Harvest Investment Services LLC acquired a new position in shares of Aura Biosciences in the 4th quarter valued at about $133,000. Finally, AlphaQuest LLC acquired a new position in shares of Aura Biosciences in the 4th quarter valued at about $136,000. 96.75% of the stock is owned by institutional investors and hedge funds.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.